|Bid||25.47 x 1300|
|Ask||25.54 x 1100|
|Day's Range||25.35 - 26.07|
|52 Week Range||11.50 - 65.24|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.18|
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Clovis Oncology, Inc. will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.S. financial markets.
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for CLVS with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $2.60 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.
BOULDER, Colo.-- -- Rubraca ® offers a new monotherapy option in Europe for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy, regardless of BRCA status Positive data from the phase 3 ARIEL3 clinical trial supported this expanded indication making Rubraca ...
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
The down-on-its-luck pharma company turned in a solid year of growth. Will it be enough to remain competitive -- or find a suitor?
BOULDER, Colo.-- -- Estimated $30.3-$30.8M in Rubraca ® sales for Q4 2018 and $95.3-$95.8M for FY2018 Q4/FY2018 Operating Results planned for February 26, 2019 Clovis Oncology , Inc. today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018. The financial information presented in this news release may be adjusted as a result of completion of customary ...
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:30 p.m.
NEW YORK, Dec. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Deepak Gulati‘s Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago. The fund is focused on offering its services to pooled investment vehicles and manages separate client-focused equity portfolios. It’s run by a team of former members of JP Morgan’s Global Equities Proprietary Trading Group […]